Reuters logo
BRIEF-Ablynx to present a post-hoc analysis of the PHASE II TITAN study with caplacizumab
May 26, 2016 / 5:21 AM / a year ago

BRIEF-Ablynx to present a post-hoc analysis of the PHASE II TITAN study with caplacizumab

May 26 (Reuters) - Ablynx Nv :

* Ablynx to present a post-hoc analysis of the Phase II TITAN study with caplacizumab in acquired TTP patients at the 21st congress of the European hematology association

* Post-hoc analysis of the TITAN data showed that treatment with caplacizumab significantly reduced a composite endpoint of major thromboembolic events and mortality Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below